ISRCTN54346737 https://doi.org/10.1186/ISRCTN54346737

Deferred registration: Quotient Sciences code: QSC303996

Submission date 04/05/2026	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 18/05/2026	**Overall study status** Deferred	
Last Edited 12/08/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Dr Nand Singh

Contact details
Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 01159749000
recruitment@weneedyou.co.uk

Type(s)
Public, Scientific

Contact name
None Clinical Study Director

Contact details
Orionintie 1
Espoo
Finland
FI-0220

+358 10 4261
clinicaltrials@orionpharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1013675

CRO code
QSC303996

Study information

Scientific Title
Deferred registration: Quotient Sciences code: QSC303996

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 17/03/2026, London – Bridge Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 0207 104 8387; londonbridge.rec@hra.nhs.uk), ref: 26/LO/0180

Primary study design
Interventional

Allocation
Randomized controlled trial

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Purpose
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Study type(s)

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date
23/09/2026

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Adult

Lower age limit
25 Years

Upper age limit
55 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
15/05/2026

Date of final enrolment
23/09/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way, Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Orion Corporation (Finland)

ROR
https://ror.org/0296s4x19

Funder(s)

Funder type

Funder Name
Orion Corporation

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available